We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals

145 hedge funds and large institutions have $1.79B invested in Ironwood Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 58 increasing their positions, 35 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 35

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

17% more capital invested

Capital invested by funds: $1.53B → $1.79B (+$261M)

7% more funds holding

Funds holding: 136145 (+9)

2% more call options, than puts

Call options by funds: $17.5M | Put options by funds: $17.1M

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

Holders
145
Holders Change
+9
Holders Change %
+6.62%
% of All Funds
3.87%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.13%
New
24
Increased
58
Reduced
35
Closed
15
Calls
$17.5M
Puts
$17.1M
Net Calls
+$385K
Net Calls Change
-$3.91M
Name Holding Trade Value Shares
Change
Change in
Stake
EL
151
Elberon LLC
Texas
-$350K -38,208 Closed
MSU
152
Mizuho Securities USA
New York
-$257K -28,059 Closed
Squarepoint
153
Squarepoint
New York
-$230K -25,074 Closed
PP
154
Paloma Partners
Connecticut
-$202K -22,083 Closed
Jane Street
155
Jane Street
New York
-$139K -15,203 Closed
SAM
156
Sectoral Asset Management
Quebec, Canada
-$117K -12,806 Closed
Creative Planning
157
Creative Planning
Kansas
-$56K -6,155 Closed
PCP
158
Proficio Capital Partners
Massachusetts
-$55K -5,970 Closed
Bessemer Group
159
Bessemer Group
New Jersey
-$22K -2,442 Closed

IRWD Hedge Fund Activity: Q2 2016 in Review

145 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2016, worth a combined $1.79B — up 17% from $1.53B a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new IRWD positions and 15 closed out — a net gain of 9 holders — while 58 added to existing stakes and 35 trimmed.

The largest buyer was Granahan Investment Management, opening a new position worth an estimated $13.2M. The largest seller was Redmile Group, cutting an estimated $45.2M.

  • 145 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2016, up from 136 in Q1 2016.
  • Funds reported $1.79B of Ironwood Pharmaceuticals stock for Q2 2016, up 17% quarter-over-quarter.
  • 24 funds opened new Ironwood Pharmaceuticals positions in Q2 2016 and 15 closed out, a net change of +9 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q2 2016 was Granahan Investment Management, an estimated $13.2M added.
  • The largest Ironwood Pharmaceuticals seller in Q2 2016 was Redmile Group, an estimated $45.2M sold.

Based on aggregated 13F filings for Q2 2016.